Heart Attack

Scottish Medicines Consortium Accepts VAZKEPA® (icosapent ethyl) to Help Reduce Cardiovascular Risk for Patients in Scotland(1)

-- VAZKEPA® (icosapent ethyl) accepted by the Scottish Medicines Consortium (SMC) for restricted use within NHSScotland, as secondary prevention in…

1 year ago

Avricore’s HealthTab Selected for Feasibility Study for Testing in Community Pharmacies in United Kingdom

VANCOUVER, British Columbia, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) (“Avricore Health” or the “Company”)…

1 year ago

Latest Research Evaluating Clinical Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the European Society of Cardiology (ESC) Congress

DUBLIN, Ireland and BRIDGEWATER, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the acceptance of…

1 year ago

HealthTab™ to Integrate CONTOUR®NEXT Family of Blood Glucose Meters to Offer Deeper Diabetes Patient Insights

VANCOUVER, British Columbia, July 19, 2023 (GLOBE NEWSWIRE) -- Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) (“Avricore Health” or the “Company”)…

1 year ago

Tonix Pharmaceuticals Announces Initiation of Enrollment in the MGH Phase 2 ‘POWER’ Study of TNX-1900 (Intranasal Potentiated Oxytocin) for the Treatment of Pediatric Obesity

Preliminary Data Suggest that Oxytocin May Simultaneously Reduce Energy Intake and Increase Energy Expenditure TNX-1900 (Intranasal Potentiated Oxytocin) May Serve…

1 year ago

Altamira Therapeutics Announces Collaboration with Heqet Therapeutics on Nanoparticle-Delivered Non-Coding RNAs for Cardiac Regeneration

HAMILTON, BERMUDA , July 05, 2023 (GLOBE NEWSWIRE) -- Heqet will test nanoparticles based on Altamira’s OligoPhore delivery platform in…

1 year ago

71% of Self-identified Snorers Have Never Consulted a Healthcare Professional

National survey identifies major obstacles to treating snoring and sleep issuesPLEASANTON, Calif., June 28, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc.…

1 year ago

The Montreal Heart Institute Welcomes FDA Approval of Colchicine for the Treatment of Cardiovascular Diseases

MONTREAL, June 23, 2023 (GLOBE NEWSWIRE) -- The Montreal Heart Institute (MHI) welcomes the approval by the United States Food…

2 years ago

Marius Pharmaceuticals Supports AXYS 2023 Virtual Family Conference, Spotlighting KYZATREX™ for XY Chromosome Variations, such as Klinefelter’s Syndrome

RALEIGH, N.C., June 20, 2023 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a patient-centric healthcare company specializing in therapies for hypogonadism or…

2 years ago